vs
Side-by-side financial comparison of CAPITAL CITY BANK GROUP INC (CCBG) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $63.5M, roughly 1.1× CAPITAL CITY BANK GROUP INC). CAPITAL CITY BANK GROUP INC runs the higher net margin — 21.6% vs -49.0%, a 70.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 6.0%). CAPITAL CITY BANK GROUP INC produced more free cash flow last quarter ($80.0M vs $-84.7M).
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
CCBG vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $63.5M | $70.6M |
| Net Profit | $13.7M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 29.3% | -56.7% |
| Net Margin | 21.6% | -49.0% |
| Revenue YoY | 6.0% | 81958.1% |
| Net Profit YoY | 4.7% | 54.9% |
| EPS (diluted) | $0.80 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $63.5M | — | ||
| Q3 25 | $65.9M | $70.6M | ||
| Q2 25 | $63.2M | — | ||
| Q1 25 | $61.5M | — | ||
| Q4 24 | $59.9M | — | ||
| Q3 24 | $59.7M | — | ||
| Q2 24 | $58.9M | — | ||
| Q1 24 | $56.5M | — |
| Q4 25 | $13.7M | — | ||
| Q3 25 | $15.9M | $-34.6M | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $16.9M | — | ||
| Q4 24 | $13.1M | — | ||
| Q3 24 | $13.1M | — | ||
| Q2 24 | $14.2M | — | ||
| Q1 24 | $12.6M | — |
| Q4 25 | 29.3% | — | ||
| Q3 25 | 32.0% | -56.7% | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 35.8% | — | ||
| Q4 24 | 29.0% | — | ||
| Q3 24 | 26.1% | — | ||
| Q2 24 | 29.3% | — | ||
| Q1 24 | 27.2% | — |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 24.2% | -49.0% | ||
| Q2 25 | 23.8% | — | ||
| Q1 25 | 27.4% | — | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 22.0% | — | ||
| Q2 24 | 24.0% | — | ||
| Q1 24 | 22.2% | — |
| Q4 25 | $0.80 | — | ||
| Q3 25 | $0.93 | — | ||
| Q2 25 | $0.88 | — | ||
| Q1 25 | $0.99 | — | ||
| Q4 24 | $0.78 | — | ||
| Q3 24 | $0.77 | — | ||
| Q2 24 | $0.83 | — | ||
| Q1 24 | $0.74 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $552.9M | $503.0M |
| Total Assets | $4.4B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $490.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $552.9M | — | ||
| Q3 25 | $540.6M | $503.0M | ||
| Q2 25 | $526.4M | — | ||
| Q1 25 | $512.6M | — | ||
| Q4 24 | $495.3M | — | ||
| Q3 24 | $476.5M | — | ||
| Q2 24 | $461.0M | — | ||
| Q1 24 | $448.3M | — |
| Q4 25 | $4.4B | — | ||
| Q3 25 | $4.3B | $577.1M | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.2B | — | ||
| Q1 24 | $4.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.6M | $-84.6M |
| Free Cash FlowOCF − Capex | $80.0M | $-84.7M |
| FCF MarginFCF / Revenue | 126.1% | -120.1% |
| Capex IntensityCapex / Revenue | 12.0% | 0.2% |
| Cash ConversionOCF / Net Profit | 6.39× | — |
| TTM Free Cash FlowTrailing 4 quarters | $150.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $21.6M | $-84.6M | ||
| Q2 25 | $32.6M | — | ||
| Q1 25 | $21.9M | — | ||
| Q4 24 | $63.6M | — | ||
| Q3 24 | $12.8M | — | ||
| Q2 24 | $24.9M | — | ||
| Q1 24 | $14.6M | — |
| Q4 25 | $80.0M | — | ||
| Q3 25 | $19.8M | $-84.7M | ||
| Q2 25 | $30.8M | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $54.9M | — | ||
| Q3 24 | $10.5M | — | ||
| Q2 24 | $23.0M | — | ||
| Q1 24 | $12.4M | — |
| Q4 25 | 126.1% | — | ||
| Q3 25 | 30.1% | -120.1% | ||
| Q2 25 | 48.7% | — | ||
| Q1 25 | 31.7% | — | ||
| Q4 24 | 91.7% | — | ||
| Q3 24 | 17.6% | — | ||
| Q2 24 | 39.0% | — | ||
| Q1 24 | 22.0% | — |
| Q4 25 | 12.0% | — | ||
| Q3 25 | 2.6% | 0.2% | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | 14.5% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 4.0% | — |
| Q4 25 | 6.39× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 2.17× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 4.86× | — | ||
| Q3 24 | 0.97× | — | ||
| Q2 24 | 1.76× | — | ||
| Q1 24 | 1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
